Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine and WBRT With or Without Hippocampal Avoidance in Brain Metastases
NCT02360215Phase 3Completed
- Sponsor
- NRG Oncology
- Start
- Jul 2015
- Primary completion
- Apr 2018
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of memantine in brain metastases (2 arms), sponsored by NRG Oncology. Primary endpoint: Percentage of Participants With Neurocognitive Failure at 6 months. Started Jul 2015; status: completed.
02
Drugs
memantine
03
Conditions
brain metastases
Beyond the preview
Go deeper on NCT02360215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02360215.